- Home
- MGNX vs PGZ Comparison
MGNX vs PGZ Comparison
Compare MGNX & PGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- PGZ
- Stock Information
- Founded
- MGNX 2000
- PGZ 2012
- Country
- MGNX United States
- PGZ United States
- Employees
- MGNX N/A
- PGZ N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- PGZ Investment Managers
- Sector
- MGNX Health Care
- PGZ Finance
- Exchange
- MGNX Nasdaq
- PGZ Nasdaq
- Market Cap
- MGNX 70.3M
- PGZ 69.6M
- IPO Year
- MGNX 2013
- PGZ N/A
- Fundamental
- Price
- MGNX $1.26
- PGZ N/A
- Analyst Decision
- MGNX Hold
- PGZ
- Analyst Count
- MGNX 10
- PGZ 0
- Target Price
- MGNX $6.83
- PGZ N/A
- AVG Volume (30 Days)
- MGNX 1.1M
- PGZ 23.0K
- Earning Date
- MGNX 05-08-2025
- PGZ 01-01-0001
- Dividend Yield
- MGNX N/A
- PGZ 12.26%
- EPS Growth
- MGNX N/A
- PGZ N/A
- EPS
- MGNX N/A
- PGZ N/A
- Revenue
- MGNX $149,962,000.00
- PGZ N/A
- Revenue This Year
- MGNX N/A
- PGZ N/A
- Revenue Next Year
- MGNX $80.86
- PGZ N/A
- P/E Ratio
- MGNX N/A
- PGZ N/A
- Revenue Growth
- MGNX 155.26
- PGZ N/A
- 52 Week Low
- MGNX $0.99
- PGZ $8.46
- 52 Week High
- MGNX $17.24
- PGZ $10.59
- Technical
- Relative Strength Index (RSI)
- MGNX 34.84
- PGZ 47.54
- Support Level
- MGNX $1.10
- PGZ $9.24
- Resistance Level
- MGNX $1.34
- PGZ $10.58
- Average True Range (ATR)
- MGNX 0.13
- PGZ 0.24
- MACD
- MGNX 0.04
- PGZ -0.01
- Stochastic Oscillator
- MGNX 77.14
- PGZ 66.42
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.